ライフサイエンスコーパス: adenosine diphosphate

1 eotides (particularly adenosine triphosphate/adenosine diphosphate).

2 needed to undock the neck linker and release adenosine diphosphate.

3 on and higher ex vivo platelet reactivity to adenosine diphosphate.

4 ctivated receptor (PAR) agonists, but not by adenosine diphosphate.

5 hosphorylation to adenosine triphosphate and adenosine diphosphate.

6 ntly as (3)H-adenosine triphosphate and (3)H-adenosine diphosphate.

7 when aggregation was induced by 5 mumol/l of adenosine diphosphate.

8 oms resolution in complex with magnesium and adenosine diphosphate.

9 specifically binds guanosine diphosphate and adenosine diphosphate.

10 sue injury and sensitization of platelets to adenosine diphosphate.

11 secretion induced by thrombin, collagen, and adenosine diphosphate.

12 cell fluorescence similar to that induced by adenosine diphosphate (10 muM) or thrombin (1 U/mL).

13 light transmittance aggregometry responses (adenosine diphosphate 20 muM) post-maintenance dose were

14 ers were defined by a relative inhibition of adenosine diphosphate (20 micromol/L)-induced platelet a

15 onstrated impaired microvessel relaxation to adenosine diphosphate (29+/-3% versus 61+/-6%, CHOL vers

16 ts [PRU]), light transmittance aggregometry (adenosine diphosphate 5 and 20 mumol/l and arachidonic a

17 Light transmittance aggregometry (adenosine diphosphate 5 to 20 muM), VerifyNow P2Y12, and

18 mbranes but is recruited to molecularly aged adenosine diphosphate actin filaments and is necessary f

19 of tissue injury and sensitized platelets to adenosine diphosphate activation.

20 Nucleotide (ATP, adenosine diphosphate, adenosine monophosphate) and nucl

21 termined after incubation with ATP (5 mM) or adenosine diphosphate (ADP) (5 mM) with or without 15 mi

22 ed greater platelet aggregation to 5-mumol/l adenosine diphosphate (ADP) (50.7 +/- 16.4% vs. 34.2 +/-

23 not reflected in corresponding increases in adenosine diphosphate (ADP) and adenosine monophosphate

24 osine triphosphate (ATP) and its precursors, adenosine diphosphate (ADP) and adenosine monophosphate

25 esponses stimulated by weak agonists such as adenosine diphosphate (ADP) and adrenaline were severely

26 tivity by optical platelet aggregation using adenosine diphosphate (ADP) and arachidonic acid (AA).

27 Light transmittance aggregation induced by adenosine diphosphate (ADP) and arachidonic acid, total

28 Platelet aggregation after adenosine diphosphate (ADP) and collagen stimuli were as

29 let signaling, the roles of TxA2 production, adenosine diphosphate (ADP) and dense-granule secretion,

30 g PI3Kgamma disaggregated following low-dose adenosine diphosphate (ADP) and had a mildly impaired ab

31 MRS showed trends for more rapid calculated adenosine diphosphate (ADP) and phosphocreatine (PCr) re

32 Adhesion occurs more slowly than with adenosine diphosphate (ADP) and requires phosphatidylino

33 n or CRP, whereas they aggregate normally to adenosine diphosphate (ADP) and spread on fibrinogen.

34 b was measured with and without low and high adenosine diphosphate (ADP) and thrombin receptor activa

35 ce of low levels of primary agonists such as adenosine diphosphate (ADP) and thrombin, or others like

36 of the platelet P2Y12 receptor (P2Y12R) for adenosine diphosphate (ADP) are associated with increase

37 We measured platelet reactivity to adenosine diphosphate (ADP) by light transmittance aggre

38 Only in adenosine diphosphate (ADP) can the mutant catalytically

39 Adenosine diphosphate (ADP) enhances platelet activation

40 Adenosine diphosphate (ADP) is a platelet agonist that c

41 Adenosine diphosphate (ADP) is known to have interesting

42 ownregulate the adenosine triphosphate (ATP)/adenosine diphosphate (ADP) metabolite ratio which stron

43 exhibiting heightened platelet reactivity to adenosine diphosphate (ADP) might be at increased risk f

44 high-resolution structure revealed that the adenosine diphosphate (ADP) moiety of the FAD prosthetic

45 ng to alphaIIbbeta3 following stimulation by adenosine diphosphate (ADP) or protease-activated recept

46 venous cangrelor, a rapid-acting, reversible adenosine diphosphate (ADP) receptor antagonist, might r

47 n-coupled nucleotide receptors: the platelet adenosine diphosphate (ADP) receptor coupled to stimulat

48 The adenosine diphosphate (ADP) receptor P2RY12 (purinergic

49 abolite that inhibits the platelet P2Y(1)(2) adenosine diphosphate (ADP) receptor, decreasing platele

50 wn regulator that operates downstream of the adenosine diphosphate (ADP) receptor, P2Y12, a target of

51 m in thrombus formation: the coinhibition of adenosine diphosphate (ADP) receptors with collagen rece

52 ht chain (RLC) phosphorylation and strain on adenosine diphosphate (ADP) release from cross-bridges i

53 pharmacologic agent that specifically causes adenosine diphosphate (ADP) ribosylation and inactivatio

54 However, inhibition of adenosine diphosphate (ADP) ribosyltransferase significa

55 We identify EspJ as a unique adenosine diphosphate (ADP) ribosyltransferase that dire

56 Adenosine diphosphate (ADP) scavengers or ADP receptor a

57 n in human platelets is largely dependent on adenosine diphosphate (ADP) signaling through the P2Y(12

58 Activation of human platelets with adenosine diphosphate (ADP) stimulated the release of VE

59 g either 2), inorganic phosphate (Pi) or 3), adenosine diphosphate (ADP) to the motility solutions.

60 lonyl-CoA, adenosine triphosphate (ATP), and adenosine diphosphate (ADP) were separated by capillary

61 ic rats to eNOS-dependent (acetylcholine and adenosine diphosphate (ADP)) and -independent (nitroglyc

62 sphate (ATP) and its first five catabolites: adenosine diphosphate (ADP), adenosine monophosphate (AM

63 Adenosine diphosphate (ADP), adenosine triphosphate (ATP

64 ergy including adenosine triphosphate (ATP), adenosine diphosphate (ADP), and adenosine monophosphate

65 vity assay, measuring platelet reactivity to adenosine diphosphate (ADP), convulxin (CVX), and thromb

66 early GPIb-IX signaling independent of Syk, adenosine diphosphate (ADP), or thromboxane A2 (TXA2), i

67 n activation with formyl-Met-Leu-Phe (fMLP), adenosine diphosphate (ADP), platelet-activating factor

68 normally induced by primary agonists such as adenosine diphosphate (ADP), thrombin, and collagen, whe

69 ity towards ATP and is strongly inhibited by adenosine diphosphate (ADP), we asked how Hsp104 functio

70 elet homeostasis and allow responsiveness to adenosine diphosphate (ADP), we developed a computationa

71 enzeneacetamide methanesulfonate), inhibited adenosine diphosphate (ADP)-, 2-methylthioADP (2-MeSADP)

72 omain, 12F1 and 6F1, bound preferentially to adenosine diphosphate (ADP)-activated platelets.

73 ity for Tim44, as well as through release of adenosine diphosphate (ADP)-bound mtHsp70 from Tim44 by

74 to demonstrate that ATP-bound Rok1, but not adenosine diphosphate (ADP)-bound Rok1, stabilizes Rrp5

75 electron microscopy (cryo-EM) structures for adenosine diphosphate (ADP)-bound, full-length, hexameri

76 utaneous coronary intervention by inhibiting adenosine diphosphate (ADP)-dependent platelet activatio

77 analyzer-ASA score > or = 550, 5 micromol/l adenosine diphosphate (ADP)-induced aggregation > or = 7

78 Adenosine diphosphate (ADP)-induced platelet reactivity

79 Adenosine diphosphate (ADP)-mediated platelet aggregatio

80 We show that the adenosine diphosphate (ADP)-reactive purinergic (P2Y12)

81 Cangrelor is a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that act

82 he rapid and robust synthesis of polymers of adenosine diphosphate (ADP)-ribose (PAR) chains, primari

83 he MERS-CoV macro domain as a more efficient adenosine diphosphate (ADP)-ribose binding module than m

84 e find that puffs acquire elevated levels of adenosine diphosphate (ADP)-ribose modified proteins and

85 The poly(adenosine diphosphate (ADP)-ribose) polymerase (PARP) pr

86 e that SIRT6 physically associates with poly[adenosine diphosphate (ADP)-ribose] polymerase 1 (PARP1)

87 Poly[adenosine diphosphate (ADP)-ribose] polymerases (PARPs)

88 with ER stress, we found elevated levels of adenosine diphosphate (ADP)-ribosylated BiP in the inact

89 Poly adenosine diphosphate (ADP)-ribosylation (PARylation) by

90 io]triphosphate (GTP gamma S) stimulation of adenosine diphosphate (ADP)-ribosylation factor (ARF) an

91 Protein adenosine diphosphate (ADP)-ribosylation is a physiologi

92 Adenosine diphosphate (ADP)-ribosylation is a post-trans

93 The key event is adenosine diphosphate (ADP)-ribosylation of the human si

94 denosine antibodies were used to detect ecto-adenosine diphosphate (ADP)-ribosyltransferase (ART) act

95 An adenosine diphosphate (ADP)-ribosyltransferase that caus

96 The adenosine diphosphate (ADP)-stimulated platelet aggregat

97 The primary outcome measure was adenosine diphosphate (ADP)-stimulated platelet fibrinog

98 ia also cause changes in the ratio of ATP to adenosine diphosphate (ADP).

99 rombogenic coagonists including collagen and adenosine diphosphate (ADP).

100 esin-1, causing tubulin-activated release of adenosine diphosphate (ADP).

101 nosine triphosphate (ATP) or activation with adenosine diphosphate (ADP).

102 othelium, and in vitro following exposure to adenosine diphosphate (ADP).

103 can be overcome by the addition of exogenous adenosine diphosphate (ADP).

104 terminates platelet aggregation responses to adenosine diphosphate (ADP).

105 ellular AMP:adenosine triphosphate (ATP) and adenosine diphosphate (ADP):ATP ratios and balancing the

106 lease associated with main power stroke) and adenosine diphosphate (ADP, release associated with mino

107 sed using agonists specific (6 and 20 microM adenosine diphosphate [ADP]) and nonspecific (6 microg/m

108 f p21, caspase cascade activation, and poly (adenosine diphosphate [ADP]) ribose (PARP) cleavage.

109 Platelet aggregation (5 and 20 muM adenosine diphosphate [ADP]), ADP-stimulated expression

110 ation, cleavage of caspase 3, and PARP (poly-adenosine diphosphate [ADP]-ribose polymerase), and incr

111 Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/

112 ith DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) in

113 ent study investigated the potential of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP-1)

114 ional DDB2 and involved the activity of poly(adenosine diphosphate [ADP]-ribose) polymerase 1.

115 tion by pan-caspase inhibitor abolished poly(adenosine diphosphate [ADP]-ribose) polymerase cleavage

116 on of caspases-8 and -3 and cleavage of poly(adenosine diphosphate [ADP]-ribose) polymerase following

117 Olaparib (AZD2281) is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor

118 positive staining for nitrotyrosine and poly(adenosine diphosphate [ADP]-ribose) polymerase-1 (PARP-1

119 uent cleavage of the DNA repair enzyme poly (adenosine diphosphate [ADP]-ribose) polymerase.

120 The nuclear enzyme poly(adenosine diphosphate [ADP]-ribose) synthase (PARS) is a

121 se-9 and -3 activation, and cleavage of poly(adenosine diphosphate [ADP]-ribose)polymerase.

122 etic cofactors (adenosine triphosphate [ATP]/adenosine diphosphate [ADP]/adenosine monophosphate [AMP

123 We have used adenosine diphosphate analogs containing electron parama

124 lephrine group with significant increases in adenosine diphosphate and adenosine monophosphate and no

125 s potentiated by G(i)-coupled receptors (eg, adenosine diphosphate and epinephrine).

126 lets responded in a dose-dependent manner to adenosine diphosphate and protease-activating peptide (P

127 trapped not ATP, but the reaction products, adenosine diphosphate and the phosphorylated RIIbeta sub

128 Because adenosine diphosphate and thromboxane A(2) have been sho

129 /-) blood, even in the presence of exogenous adenosine diphosphate and thromboxane A(2).

130 d with variation in the platelet response to adenosine diphosphate and/or the collagen-mimetic peptid

131 Soluble apyrase reduced renal ATP, adenosine diphosphate, and adenosine monophosphate, but

132 structure of MsbA in complex with magnesium, adenosine diphosphate, and inorganic vanadate (Mg.ADP.Vi

133 mal platelet aggregation to 5 and 20 mumol/l adenosine diphosphate, and VerifyNow P2Y12 platelet resp

134 The potent intravenous adenosine diphosphate antagonist cangrelor substantially

135 In addition to anticoagulation and an adenosine diphosphate-antagonist an adjunct therapy with

136 d stronger platelet inhibition than ASA with adenosine diphosphate as the agonist, and combination th

137 pyrase (CD39 converts adenosine triphosphate/adenosine diphosphate [ATP/ADP] to adenosine monophospha

138 amma-methyleneadenosine 5'-triphosphate, and adenosine diphosphate beryllium fluoride.

139 structure of SecA with and without magnesium-adenosine diphosphate bound to the high-affinity ATPase

140 migration of primary microglial cells toward adenosine diphosphate by 257, 247, 301, 394, and 345% fo

141 n/epinephrine agonist cartridge and collagen/adenosine diphosphate (CADP) agonist cartridge, VerifyNo

142 by platelet aggregation to arachidonic acid, adenosine diphosphate, collagen and epinephrine, Platele

143 Calculated cytosolic adenosine diphosphate concentration decreased, whereas t

144 HMW multimers and the closure time with adenosine diphosphate (CT-ADP), a point-of-care measure

145 r the addition of glutamate and malate (GM), adenosine diphosphate (d), succinate (S) and octanoyl ca

146 High on-treatment platelet reactivity to adenosine diphosphate during clopidogrel therapy is a we

147 ed platelet aggregation to arachidonic acid, adenosine diphosphate, epinephrine, and platelet functio

148 e redox potential and adenosine triphosphate/adenosine diphosphate failed to reach a new steady state

149 lso exhibited activity towards quercetin and adenosine diphosphate glucose (ADPG), kaempferol and UDP

150 Adenosine diphosphate glucose pyrophosphorylase (AGPase)

151 ransgenic reports point to the importance of adenosine diphosphate glucose pyrophosphorylase in contr

152 transferase (GT) that transfers glucose from adenosine diphosphate glucose to a glucan chain acceptor

153 e >> 5'adenosine-triphosphate (ATP) > or = 5'adenosine-diphosphate > 5'uridine-triphosphate > or = 5'

154 wing order of potency: thrombin > LPA = ADP (adenosine diphosphate) > S1P.

155 Poly(ADP-ribose) polymerase-1 (PARP-1) (ADP, adenosine diphosphate) has a modular domain architecture

156 ency, exhibit limited adenosine triphosphate/adenosine diphosphate hydrolysis activity, and fail to s

157 are lacking for PARG, the specific inhibitor adenosine diphosphate (hydroxymethyl)pyrrolidinediol (AD

158 regation, produce thromboxane A2, or secrete adenosine diphosphate in response to submaximal gamma-th

159 omain is protected from dephosphorylation by adenosine diphosphate in the complete absence of the bet

160 Platelet function parameters included adenosine diphosphate-induced (20 and 5 micromol/L) maxi

161 After randomization, maximal adenosine diphosphate-induced (20 micromol/L) platelet a

162 bolished the 3-fold prolongation in collagen adenosine diphosphate-induced closure times seen in exte

163 reactivity was increased when measured using adenosine diphosphate-induced light transmission aggrego

164 telet activation, and is mediated in part by adenosine diphosphate-induced platelet activation.

165 Maximum adenosine diphosphate-induced platelet aggregation (20 m

166 Adenosine diphosphate-induced platelet aggregation was a

167 e (AppCHClppA) are competitive inhibitors of adenosine diphosphate-induced platelet aggregation, whic

168 edly lower PR at all times (5- and 20-microM adenosine diphosphate-induced, and 15- and 25-microM thr

169 pirin, glycoprotein IIb/IIIa inhibitors, and adenosine diphosphate inhibitors.

170 creatine kinase catalyzed phosphorylation of adenosine diphosphate is examined in two independent ser

171 cteroids, thus indicating that extracellular adenosine diphosphate is important during nodulation.

172 Adenosine triphosphate/adenosine diphosphate is metabolized to adenosine throug

173 in intramuscular inorganic phosphate, H(+) , adenosine diphosphate, lactate and phosphocreatine deple

174 s converting adenosine triphosphate (ATP) to adenosine diphosphate or adenosine monophosphate.

175 let aggregation and degranulation induced by adenosine diphosphate or collagen were diminished but we

176 ns diminished channel responses to magnesium adenosine diphosphate or diazoxide, while dominant KCNJ1

177 n vitro stimulation of PT-VWD platelets with adenosine diphosphate or thrombin demonstrates a signifi

178 ifferences in responsiveness of platelets to adenosine diphosphate or thrombin receptor agonist pepti

179 Collagen-, collagen-related peptide-, adenosine diphosphate-, or thrombin-induced platelet agg

180 We hypothesized that nicotinamide adenosine diphosphate oxidase 2 (Nox2) plays an importan

181 Nicotinamide adenosine diphosphate oxidase 2 knockout was also associ

182 predicted aggregation to 2 muM and 10 muM of adenosine diphosphate (P = .02 and <.001, respectively)

183 uent use of radial access and novel platelet adenosine diphosphate P2Y12 receptor inhibitors.

184 ctivity, especially with tests measuring the adenosine diphosphate-P2Y12 receptor pathway, without si

185 chondrial inner membrane, thereby uncoupling adenosine diphosphate phosphorylation from nutrient oxid

186 caspase activation and the cleavage of poly(adenosine diphosphate) (poly(ADP)) ribose polymerase.

187 in the liver, whereas adenosine triphosphate/adenosine diphosphate ratios remained low.

188 phate levels, whereas adenosine triphosphate/adenosine diphosphate ratios were low.

189 ficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidog

190 severity of the disease, early treatment of adenosine diphosphate receptor antagonists at presentati

191 rials are needed to define the role of newer adenosine diphosphate receptor antagonists in this setti

192 Prasugrel and ticagrelor, new P2Y12-adenosine diphosphate receptor antagonists, are associat

193 The P2Y12-adenosine diphosphate receptor blockade was assessed by

194 The standard adenosine diphosphate receptor blocker in this setting i

195 Ticagrelor is a direct-acting P2Y12-adenosine diphosphate receptor blocker.

196 Guidelines recommend the use of adenosine diphosphate receptor inhibitor (ADPri) therapy

197 nction testing to guide choice and dosing of adenosine diphosphate receptor inhibitor (ADPri) therapy

198 This study used data from the Treatment With Adenosine Diphosphate Receptor Inhibitors-Longitudinal A

199 2365 patients enrolled in the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal

200 Using TRANSLATE-ACS (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal

201 d States TRANSLATE-ACS study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal

202 ive from 233 hospitals in the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal

203 The Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal

204 e analogue, is an intravenous blocker of the adenosine diphosphate receptor P2Y(12).

205 cleotide exchange factor CalDAG-GEFI and the adenosine diphosphate receptor P2Y12 as independent path

206 ivation of integrin alphaIIbbeta3, while the adenosine diphosphate receptor P2Y12, the target for ant

207 Cangrelor is a potent intravenous adenosine diphosphate-receptor antagonist that in the CH

208 the availability of rapidly-acting platelet adenosine diphosphate-receptor antagonists, the need for

209 groups of patients, the phosphocreatine and adenosine diphosphate recovery half-times were almost tw

210 isolated terminals, we tested 8-bromo-cyclic adenosine diphosphate ribose (8Br-cADPr), a competitive

211 ribosyltransferases catalyze the transfer of adenosine diphosphate ribose (ADP-ribose) from nicotinam

212 brane protein that converts NAD primarily to adenosine diphosphate ribose (ADPR) and a small amount o

213 It metabolizes NAD(+) to adenosine diphosphate ribose (ADPR) and cyclic ADPR, reg

214 However, these enzymes also produce adenosine diphosphate ribose (ADPR) and nicotinic acid a

215 where, involves the release of mitochondrial adenosine diphosphate ribose (ADPR) or nicotinamide aden

216 It is activated by intracellular adenosine diphosphate ribose (ADPR) through a diphosphor

217 f two potent Ca(2+) releasing agents: cyclic adenosine diphosphate ribose (cADPR) from nicotinamide a

218 of the calcium-mobilizing metabolite, cyclic adenosine diphosphate ribose (cADPR), from nicotinamide

219 k incorporates the signaling molecule cyclic adenosine diphosphate ribose (cADPR).

220 ates the cytosolic signaling molecule cyclic adenosine diphosphate ribose (cADPR).

221 e ribose (ADPR) and a small amount of cyclic adenosine diphosphate ribose (cADPR).

222 Blockade of the cyclic adenosine diphosphate ribose (cADPR)/ryanodine-sensitive

223 ng agents sphingosine-1-phosphate and cyclic adenosine diphosphate ribose exhibited weaker ABA-stimul

224 accompanied by caspase-3 activation and poly-adenosine diphosphate ribose polymerase (PARP) cleavage

225 age during transplantation can activate poly-adenosine diphosphate ribose polymerase (PARP) resulting

226 ial growth factor, 3-nitrotyrosine, and poly(adenosine diphosphate ribose) expression in lung tissue.

227 NBC has rationalized clinical trials of poly(adenosine diphosphate ribose) polymerase (PARP) inhibito

228 ired IHHs displayed caspase activation, poly(adenosine diphosphate ribose) polymerase cleavage, and a

229 In cells deficient in the telomeric poly(adenosine diphosphate ribose) polymerase tankyrase 1, si

230 entification of an unexpected molecule, poly(adenosine diphosphate ribose), that may be implicated in

231 on stress, a defect accentuated by poly-ADP (adenosine diphosphate) ribose polymerase inhibitors.

232 Similarly, the NAD-dependent poly(adenosine diphosphate)ribose polymerase 1 (PARP1) may af

233 ) resulting in the generation of polymers of adenosine diphosphate-ribose (PAR).

234 PM2 channels were activated by intracellular adenosine diphosphate-ribose and blocked by flufenamic a

235 rial dysfunction, caspase cleavage, and poly adenosine diphosphate-ribose polymerase (PARP) degradati

236 ROS), 3-nitrotyrosine (marker of RNS), poly(adenosine diphosphate-ribose) (PAR, marker of PARP activ

237 of caspase-2 and caspase-3, cleavage of poly(adenosine diphosphate-ribose) (poly(ADP-ribose)) polymer

238 noblots demonstrated adaphostin induced poly(adenosine diphosphate-ribose) polymerase (PARP) cleavage

239 ected by caspases-3 and -8 cleavage and poly(adenosine diphosphate-ribose) polymerase (PARP) degradat

240 a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibiti

241 Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibito

242 ated the effects of a novel ultrapotent poly(adenosine diphosphate-ribose) polymerase (PARP) inhibito

243 ding DNA fragmentation and cleavage of poly (adenosine diphosphate-ribose) polymerase (PARP), as well

244 f caspase-3, -8, and -9 and cleavage of poly(adenosine diphosphate-ribose) polymerase (PARP).

245 gen species (RNS) and the activation of poly(adenosine diphosphate-ribose) polymerase (PARP).

246 the human bax promoter and found that poly (adenosine diphosphate-ribose) polymerase 1 recruited the

247 mitochondrial membrane potential, and poly (adenosine diphosphate-ribose) polymerase cleavage.

248 C-alpha, phospho-PKC-beta1, and cleaved poly(adenosine diphosphate-ribose) polymerase in post-CP/Rep

249 HR) as measured by hypersensitivity to poly (adenosine diphosphate-ribose) polymerase inhibition and

250 high tidal volume ventilation plus the poly-(adenosine diphosphate-ribose) polymerase inhibitor 3-ami

251 e II prospective clinical trial of the poly-(adenosine diphosphate-ribose) polymerase inhibitor olapa

252 nstability in response to radiation and poly(adenosine diphosphate-ribose) polymerase inhibitors, com

253 cyclin-dependent kinase inhibitors and poly(adenosine diphosphate-ribose) polymerase inhibitors.

254 ospho-PKC-alpha, phospho-PKC-beta1, and poly(adenosine diphosphate-ribose) polymerase were quantified

255 actor, caspase 3, caspase 8, caspase 9, poly(adenosine diphosphate-ribose) polymerase, B-cell lymphom

256 Subsequent to the break, poly(adenosine diphosphate-ribose) polymerase-1 enzymatic act

257 activity of caspase-3/7 and cleavage of poly(adenosine diphosphate-ribose) polymerase.

258 r 1) prevents it from inhibiting PARP1 [poly(adenosine diphosphate-ribose) polymerase], a critical DN

259 an essential substrate for sirtuins and poly(adenosine diphosphate-ribose) polymerases (PARPs), which

260 other enzymes such as the sirtuins and poly(adenosine diphosphate-ribose) polymerases.

261 luorthanatrace (FTT) depicts activated poly (adenosine diphosphate-ribose)polymerase (PARP) expressio

262 The poly(adenosine diphosphate-ribose)polymerase (PARP) family of

263 ed forms of caspases-2 and -3, bax, and poly-adenosine diphosphate-ribose-polymerase (PARP) by Wester

264 ), enhanced cell death (caspase 3/7 and poly[adenosine diphosphate-ribose] polymerase activity, chrom

265 by caspase-8, -9, and -3 and PARP (poly-ADP [adenosine diphosphate]-ribose polymerase) cleavage and d

266 A allele contributed to significantly lower adenosine diphosphate ribosyl transferase (ADPRT)/PARP-1

267 the synthesis and distribution of the unique adenosine diphosphate-ribosylating and vacuolating Commu

268 ng to multiple low-affinity sites comprising adenosine diphosphate ribosylation factor 1 (Arf-1)-guan

269 interacts with and regulates the activity of adenosine diphosphate ribosylation factor 6 (ARF6), a sm

270 lized guanine nucleotide exchange factor for adenosine diphosphate ribosylation factor GTPases.

271 Furthermore, we identified the adenosine diphosphate ribosylation factor-1 GTPase to be

272 The Golgi-localized, gamma-ear-containing, adenosine diphosphate ribosylation factor-binding protei

273 idopsis thaliana AGD1 gene encodes a class 1 adenosine diphosphate ribosylation factor-gtpase-activat

274 the small guanosine triphosphatase (GTPase) adenosine diphosphate ribosylation factor-like protein 1

275 evidence to suggest that Kes1p may regulate adenosine diphosphate-ribosylation factor (ARF) function

276 ation of p47phox, PLD-containing organelles, adenosine diphosphate-ribosylation factor 1, RhoA, prote

277 ads to activation of the Rac1 GTPase through adenosine diphosphate-ribosylation factor 6 (Arf6).

278 The antigen representing adenosine diphosphate-ribosylation factor GTPase activat

279 Adenosine diphosphate ribosyltransferases (ARTDs; ARTD1-

280 enable thrombin-induced TxA2 production and adenosine diphosphate secretion, necessary steps in secr

281 ship between oxygen consumption (baseline or adenosine diphosphate stimulated) and human leukocyte an

282 tains an RGD motif and binds equally well to adenosine diphosphate-stimulated human and rodent platel

283 Adenosine diphosphate-stimulated mitochondrial respirati

284 In vitro, L5 enhanced adenosine diphosphate-stimulated platelet aggregation tw

285 Both resting and adenosine diphosphate-stimulated platelet IIb/IIIa recep

286 Cs (p < .01), with an attenuated response to adenosine diphosphate stimulation (p < .01).

287 etion in response to thrombin, collagen, and adenosine diphosphate stimulation were all within normal

288 ative phosphorylation was investigated using adenosine diphosphate stimulation.

289 in platelets depends exclusively on secreted adenosine diphosphate that stimulates G(i) signaling pat

290 tion, and they responded to stimulation with adenosine diphosphate, thrombin, and the PAR4 thrombin r

291 drolysis of adenosine triphosphate (ATP) and adenosine diphosphate to adenosine monophosphate on NK c

292 d upon the enzymatic transphosphorylation of adenosine diphosphate to adenosine triphosphate was used

293 Application of exogenous adenosine diphosphate to silenced GS52 roots restored no

294 iphosphate synthases, adenosine triphosphate/adenosine diphosphate translocase, and catalase (all p <

295 light transmittance aggregometry with 5 muM adenosine diphosphate, VerifyNow P2Y(12), and vasodilato

296 gation (PA) in response to 20 micro mol/L of adenosine diphosphate was measured with turbidimetric ag

297 as the P2Y1-specific agonist 2-methylthio-5'-adenosine diphosphate was, again, only effective in a sm

298 r glycoprotein VI agonists, but responses to adenosine diphosphate were impaired.

299 phosphates (e.g., adenosine triphosphate and adenosine diphosphate) were readily degraded into a mono

300 switch I suggest a role for it in "ejecting" adenosine diphosphate when kinesin initially binds to th